Abbott seen posting modest Q1 earnings amid Nutrition segment slowdown

Abbott Laboratories is expected to report modest first-quarter earnings, with analysts anticipating that a slowdown in its Nutrition segment will weigh on overall results. The company's performance will be closely watched for signs of recovery in the infant formula market and continued strength in its medical devices and diagnostics divisions.